Most large studies are funded by large pharmaceutical companies, and there is no incentive for them to continue research of drugs once they are off-patent
Nonetheless, to date the only FDA- and EMA-approved NRF2 activator for the treatment of relapsing-remitting MS and psoriasis is DMF, and its therapeutic potential in ALS patients in terms of efficacy, safety and tolerability, is now being evaluated in a phase-II clinical trial [313]
Clinically observed reductions in lean mass during medically induced weight loss [40] are therefore consistent with a substrate-sensitive vulnerability affecting skeletal muscle maintenance
Cysts, lipomas, and reactive lymph nodes account for the overwhelming majority of cases
The Case for Morning Supplementation For the majority of people, the morning is the most effective window for both glutathione and collagen
Vasiliou, V., Pappa, A